학술논문
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Document Type
Abstract
Author
Ray-Coquard, I.L.; Leary, A.; Pignata, S.; Cropet, C.; Martin, A.J. Gonzalez; Bogner, G.; Yoshida, H.; Vergote, I.B.; Colombo, N.; Maenpaa, J.; Selle, F.; Schmalfeldt, B.; Scambia, G.; Alia, E.M. Guerra; Lefeuvre-Plesse, C.; Belau, A.; Lortholary, A.; Gropp-Meier, M.; Pujade-Lauraine, E.; Harter, P.
Source
In Annals of Oncology September 2022 33 Supplement 7:S1396-S1397
Subject
Language
ISSN
0923-7534